Al Sandrock is the President and CEO at Voyager Therapeutics, a gene therapy company focused on developing treatments for neurological disorders.
Al Sandrock is the President and CEO at Voyager Therapeutics, a gene therapy company focused on developing treatments for neurological disorders. The company's pipeline includes programs targeting Alzheimer's disease through the tau protein with both an antibody and a gene therapy, in addition to other preclinical studies. Prior to his role at Voyager, Sandrock spent over 20 years at Biogen, where he served as Executive Vice President of R&D and was involved in the FDA approval of Aduhelm for Alzheimer's.
Full founder directory · Investor directory · Company funding database · Fundraising library